Tri Locum Partners LP

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$506.1M2026 Q3
Positions18
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.80.1%

Tri Locum Partners LP reported 18 positions worth $506.1M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: VRTX (13.7%).

10 / 18 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 VRTXVertex Pharmaceuticals Inc$69.5M13.73%132,896——+2.9%
▸ 2 LLYEli Lilly$59.0M11.66%51,015——+23.7%
▸ 3 TEVATeva Pharmaceutical Industries$48.5M9.57%1,223,725——+7.5%
▸ 4 AMRXAmneal Pharmaceuticals$46.9M9.26%2,326,733——+6.2%
▸ 5 DXCMDexcom$42.2M8.34%489,400——-5.4%
▸ 6 JAZZJazz Pharmaceuticals$37.1M7.33%160,321——+3.6%
▸ 7 ARGXArgenx$29.1M5.76%30,399——-0.8%
▸ 8 ASNDAscendis Pharma A/S$27.0M5.33%118,384——+20.9%
▸ 9 AXSMAxsome Therapeutics$26.4M5.22%143,338——-25.7%
▸ 10 JNJJohnson & Johnson$19.5M3.85%73,559——+6.7%

Pro Feature

The remaining 8 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Tri Locum Partners LP hold as of Q3 2026?

Tri Locum Partners LP reported 18 positions worth $506.1M in its Q3 2026 13F filing. Largest positions: VRTX (13.7%), LLY (11.7%), TEVA (9.6%), AMRX (9.3%) and DXCM (8.3%).

What did Tri Locum Partners LP buy in Q3 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Tri Locum Partners LP sell in Q3 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.